Mahsa Babaei1, Gheorghe M Borja Zamfir1, Xiao Chen1, Hanne Bjerre Christensen1, Mette Kristensen1, Jens Nielsen1,2,3, Irina Borodina1. 1. The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet Building 220, DK-2800 Kgs. Lyngby, Denmark. 2. Department of Biology and Biological Engineering, Chalmers University of Technology, 412 96, Gothenburg, Sweden. 3. BioInnovation Institute, Ole Måløes Vej 3, 2200, Copenhagen N, Denmark.
Abstract
Rosmarinic acid is a hydroxycinnamic acid ester commonly found in the Boraginaceae and Lamiaceae plant families. It exhibits various biological activities, including antioxidant, anti-inflammatory, antibacterial, antiallergic, and antiviral properties. Rosmarinic acid is used as a food and cosmetic ingredient, and several pharmaceutical applications have been suggested as well. Rosmarinic acid is currently produced by extraction from plants or chemical synthesis; however, due to limited availability of the plant sources and the complexity of the chemical synthesis method, there is an increasing interest in producing this compound by microbial fermentation. In this study, we aimed to produce rosmarinic acid by engineered baker's yeast Saccharomyces cerevisiae. Multiple biosynthetic pathway variants, carrying only plant genes or a combination of plant and Escherichia coli genes, were implemented using a full factorial design of experiment. Through analysis of variances, the effect of each enzyme variant (factors), together with possible interactions between these factors, was assessed. The best pathway variant produced 2.95 ± 0.08 mg/L rosmarinic acid in mineral medium with glucose as the sole carbon source. Increasing the copy number of rosmarinic acid biosynthetic genes increased the titer to 5.93 ± 0.06 mg/L. The study shows the feasibility of producing rosmarinic acid by yeast fermentation.
Rosmarinic acid is a hydroxycinnamic acid ester commonly found in the Boraginaceae and Lamiaceae plant families. It exhibits various biological activities, including antioxidant, anti-inflammatory, antibacterial, antiallergic, and antiviral properties. Rosmarinic acid is used as a food and cosmetic ingredient, and several pharmaceutical applications have been suggested as well. Rosmarinic acid is currently produced by extraction from plants or chemical synthesis; however, due to limited availability of the plant sources and the complexity of the chemical synthesis method, there is an increasing interest in producing this compound by microbial fermentation. In this study, we aimed to produce rosmarinic acid by engineered baker's yeast Saccharomyces cerevisiae. Multiple biosynthetic pathway variants, carrying only plant genes or a combination of plant and Escherichia coli genes, were implemented using a full factorial design of experiment. Through analysis of variances, the effect of each enzyme variant (factors), together with possible interactions between these factors, was assessed. The best pathway variant produced 2.95 ± 0.08 mg/L rosmarinic acid in mineral medium with glucose as the sole carbon source. Increasing the copy number of rosmarinic acid biosynthetic genes increased the titer to 5.93 ± 0.06 mg/L. The study shows the feasibility of producing rosmarinic acid by yeast fermentation.
Rosmarinic
acid (RA) is a polyphenolic
antioxidant that occurs in some members of the Lamiaceae family, and
is one of the active compounds in medical herbs such as rosemary Rosmarinus officinalis, sage Salvia officinalis, and lemon balm Melissa officinalis. It displays
numerous antioxidant, anti-inflammatory, antitumor, anticancer, and
antimicrobial activities. The antioxidant activity of RA is higher
than that of vitamin E.[1] Several clinical
trials found RA effective in the treatment of asthma, allergies, and
reactive airway diseases.[2−5] Additionally, rosmarinic acid is a neuroprotective
and cognitive-enhancer molecule, as shown in treatment of Parkinson
and prevention of Alzheimer’s diseases in rat models.[6,7]Similar to most of the plant-derived bioactive compounds,
RA is
currently obtained from plant cells. The highest content of 31% of
dry weight (6.4 g/L) was reported for cell cultures of S.
officinalis by feeding 0.1 g/L L-phenylalanine after 25 days.[8] Considering that a suspension cell culture of
plants is difficult to scale up, lacks the specificity for RA production,
and requires long-term cultivation, there is a need to develop less
expensive and simpler processes for RA production. Microbial cell
factories, such as Saccharomyces cerevisiae, have
the potential to serve as a host for heterologous production of plant
metabolites and are well-amenable for engineering and large scale
fermentation on inexpensive medium.[9,10]Rosmarinic
acid consists of two aromatic rings with two hydroxyl
groups on each ring (Figure ), which give the free radical scavenging ability against
superoxide anions and hydroxyl radicals.[11] The RA biosynthetic enzymes were studied in suspension cell cultures
of Plectranthus scutellarioides (Coleus blumei) by Petersen et al.[12] (Figure ). In “plant pathway”,
the two parts of RA molecule, caffeic acid (CA) and 3,4-dihydroxyphenyllactic
acid (3,4-DHPL), are synthesized separately from L-phenylalanine and
L-tyrosine, respectively. The first step is the deamination of both
amino acids, to form t-cinnamic acid from L-phenylalanine,
and 4-hydroxyphenylpyruvic acid (4-HPP) from L-tyrosine. Next, t-cinnamic acid is hydroxylated in positon 4 of the phenolic
ring by cytochrome P450 monooxygenase cinnamate 4-hydroxylase (C4H) to form p-coumaric acid (pCA). The
following step is the activation of pCA by 4-coumaryl CoA-ligase (4CL). In the other branch, 4-HPP is reduced to 4-hydroxyphenyllactic
acid (4-HPL). Rosmarinic acid synthase (RAS) catalyzes
the coupling of 4-coumaroyl-CoA and 4-HPL with concurrent release
of coenzyme A. This enzyme requires unimolar amounts of both substrates
to form one mole of product, 4-coumaroyl-4′-hydroxyphenyllactic
acid. This compound is then hydroxylated in positions 3 and 3′
by cytochrome P450 hydroxycinnamoyl-hydroxyphenyllactate 3- and 3′-hydroxylase
(CYP98A14). These final hydroxylation steps are considered
to be the main flux-limiting steps in the production of rosmarinic
acid.[13] The final reaction of rosmarinic
acid production by the pathway described (and shown in black in Figure ) can be summarized
as:L-tyrosine + L-phenylalanine + 4NADH + ATP → rosmarinic
acid + 2NH3 + 4NAD+
Figure 1
Biosynthetic plant pathway
to rosmarinic acid in plant cell C. blumei(14) (black compounds
and arrows), and chimeric pathway (orange compounds and arrows). The
enzymes involved are abbreviated in blue, PAL = phenylalanine
ammonia lyase, C4H = cinnamic acid 4-hydroxylase, 4CL = 4-coumaryl CoA-ligase, TAT = tyrosine
aminotransferase, HPPR = hydroxyphenylpyruvate reductase, RAS = “rosmarinic acid synthase”, hydroxycinnamoyl-CoA/hydroxyphenyllactate
hydroxycinnamoyltransferase, CYP98A14 = 4-coumaroyl-4′-hydroxyphenyllactate
3/3′-hydroxylases, EchpaBC = E. coli 4-hydroxyphenylacetate 3-hydroxylase complexes B and C.
Biosynthetic plant pathway
to rosmarinic acid in plant cell C. blumei(14) (black compounds
and arrows), and chimeric pathway (orange compounds and arrows). The
enzymes involved are abbreviated in blue, PAL = phenylalanine
ammonia lyase, C4H = cinnamic acid 4-hydroxylase, 4CL = 4-coumaryl CoA-ligase, TAT = tyrosine
aminotransferase, HPPR = hydroxyphenylpyruvate reductase, RAS = “rosmarinic acid synthase”, hydroxycinnamoyl-CoA/hydroxyphenyllactate
hydroxycinnamoyltransferase, CYP98A14 = 4-coumaroyl-4′-hydroxyphenyllactate
3/3′-hydroxylases, EchpaBC = E. coli 4-hydroxyphenylacetate 3-hydroxylase complexes B and C.Cytochrome P450s are heme-containing monoxygenases. Using
molecular
oxygen as a substrate, they insert one oxygen atom into an aliphatic
position of an organic substrate and reduce the other oxygen atom
to water.[15] The successful expression and
activation of CYP enzymes in cells relies on two
main factors: (i) coupling the P450 enzyme to electron-donating protein,
cytochrome P450 reductase (CPR), and (ii) colocalizing
of both CYP and CPR to the membrane
of endoplasmic reticulum (ER) anchored via their N-terminus.[16] The expression of a functioning CYP–CPR enzyme pairs in bacterial cell factories such as Escherichia
coli, where CPR and ER membrane are absent,
is problematic. Hence, for RA production, Bloch and Schmidt-Dannert
developed a “chimeric pathway” for E. coli, by 3-hydroxylation of the substrate precursors prior to RA ester
formation.[17] In this method, they used
the E. coli 4-hydroxyphenylacetate 3-hydroxylase
complex (EchpaBC) to hydroxylate pCA to caffeic acid, and 4-HPL to 3,4-DHPL.[18] RA synthase can act on caffeic acid and 3,4-DHPL, producing RA (Figure ). But the enzyme
shows almost 10 times lower affinity for 3,4-DHPL as substrate compared
to 4-HPL.[19] Also, the enzyme complex EchpaBC is reported to catalyze the hydroxylation of L-tyrosine
to L-DOPA (L-(3,4-dihydroxy)phenylalanine)[20] reducing the L-tyrosine pool as the main amino acid precursor for
RA production. The optimized E. coli strain of Bloch
and Schmidt-Dannert was shown to produce 0.65 ± 0.11 mg/L of
rosmarinic acid from glycerol.[17] The main
issue with this strain is that the catalytic efficiency of the EchpaBC enzyme complex is probably not so high for 4-HPL,
as isorinic acid (the ester conjugate of 4-HPL and caffeic acid) was
detected in much higher concentration than rosmarinic acid. To increase
this catalytic activity and achieve higher concentration of 3,4-DHPL,
Yao et al. used a variant of lactate dehydrogenase enzyme (LDH) from Lactobacillus pentosus and coexpressed it together with EchpaBC.[21] By feeding the precursor caffeic acid, they
achieved the highest titer of 130 mg/L.[22,23] Further engineering
the strain to aim for higher L-tyrosine titer is reported by Li et
al., who in their work reached an RA titer of 4.5 mg/L from glucose.[24] In the same study, 172 mg/L RA was obtained
by coculturing three E. coli strains on complex medium.
The genetic modifications of these three strains were similar to that
in the previous works.[22,23] The difference was in segregation
of the production of precursors and RA into three different strains:
the first strain producing caffeic acid from glucose, the second strain
produced 3,4-DHPL from glucose, and the third strain conjugated caffeic
acid and 3,4-DHPL to rosmarinic acid.[24] It will however be difficult to scale up a process based on coculturing
of several strains, as it will require maintaining a stable strain-to-strain
ratio throughout the fermentation.As the basic step in engineering
a heterologous pathway, one needs
to find the optimal combination of enzyme homologues in the pathway,
in order to have the highest conversion of intermediates to the final
product of interest. Owing to investigations of the key enzymes involved
in biosynthesis of rosmarinic acid in several plant species of the
family Lamiaceae during the past decade, there are several candidates
for the genes CYP98A14, RAS, and TAT, with coding DNA sequences available.[25−29] In this case, the design of experiments (DOE) serves
as an efficient tool for systematic screening of the combinatorial
space of enzyme homologues and interpretation of the results.[30,31] With the full factorial design, all possible combinations of the
levels across all the factors are taken into account to analyze the
effects of each factor, evaluating these effects at several levels
and, more importantly, the possible interactions between the factors.
The obtained main effects and interaction plots together with the
magnitude of effect for each single factor or interaction can provide
an insight into the biological systems. In the case of large combinatorial
libraries, fractional factorial DOE was shown to be a powerful tool
for the algorithmic design of yeast strains to improve itaconic acid
titer.[32]Eukaryotic cells such as S. cerevisiae have been
shown to be an ideal host for production of plant-derived bioactive
compounds. The native cytochrome P450 reductase of S. cerevisiae (NCP1 gene, accession code P16603) has 31% identity
to protein sequence of CPR from two rosmarinic acid
producer cells, S. officinalis and P. scutellarioides, making S. cerevisiae a potential host for production
of rosmarinic acid. We herein provide the first description of rosmarinic
acid production from glucose in mineral media using the plant originated
enzymes expressed in a microbial host.
Results and Discussion
Investigation
of Rosmarinic Acid Degradation in Fermentation
Medium
A major issue with microbial production of bioactive
phenolic compounds such as RA is the degradation of these compounds
in the presence of oxygen, heat, and light.[33,34] Previous electrochemical studies have shown that RA is oxidized
in a pH-dependent two-step reaction, withdrawing two electrons from
each aromatic ring, four electrons in total.[35] Additionally, when produced in a cell, RA can be hydrolyzed into
caffeic acid and 3,4-DHPL by the action of reversible rosmarinic acid
synthase.[36] We tested the method for RA
extraction with ethyl acetate described by Bloch and Schmidt-Dannert,[17] but could not extract RA added to a liquid medium.
Extraction with a more polar solvent (acetonitrile) also gave a very
low efficiency (1%). As RA solubility is reported to increase in binary
solvent mixtures of ethanol and water, we mixed the aqueous sample
of RA with ethanol in 1:1 v/v ratio and in this way could detect 80–90%
of the added RA. To prevent the oxidation of RA during the sample
preparation, we added 0.01% butylated hydroxytoluene as an antioxidant,
and in this way, we could detect 99% of the added RA (Supporting Information, Table S1). Next, we tested the stability of RA
in yeast cultures. For this, we supplemented the mineral medium (pH
6.0) with 1 g/L RA and incubated it for 3 days at 30 °C with
or without yeast cells. To our surprise, we could recover 90% of RA
at the end of the cultivation from the cells-containing broth, but
less than 3% from the medium without cells. We hypothesized that RA
was degraded less in the cell culture due to pH decrease over the
course of fermentation because of the production of organic acids
by yeast. Indeed, when we repeated the experiment with the medium
without cells set to pH 3.0, no degradation of RA was observed. To
prevent the degradation of RA in the course of cultivation, we tested
the addition of 10 mM ascorbic acid as antioxidant. The recovery of
RA after 3 days was 94% and 91% in the absence or presence of yeast
cells, respectively (Supporting Information, Figure S1). We could thus conclude that nonengineered S. cerevisiae does not degrade RA and that RA can be stabilized in the medium
by the addition of ascorbic acid, which was applied in the subsequent
cultivations in this work.The precursor molecules for RA biosynthesis
in plants are L-tyrosine and L-phenylalanine (Figure ). These amino acids also serve as the precursor
for numerous biosynthesis pathways of commercial interest, including
flavonoids,[37] stilbenoids,[38] and fusel alcohols,[39] to name
a few. The engineering strategies to increase the production of these
amino acids have been extensively studied on yeast before. The most
common strategies are the alleviation of the allosteric feedback regulation
of the DAHP synthase and chorismate mutase genes, by expressing mutated
version of ARO4 (ARO4) and ARO7 (ARO7), overexpression of heterologous
shikimate kinase AroL from E. coli (EcAroL), and deletion of ARO10 and PDC5 to block the aromatic amino acids degradation
pathway (Ehrlich pathway).[40,41] We implemented these
modifications into S. cerevisiae CEN.PK113-7D strain[42] to create the platform strain for the production
of RA (Figure ). The
next step, was to convert aromatic amino acids into precursors for
rosmarinic acid production. As L-tyrosine has one hydroxyl group in
the aromatic ring, replacing L-phenylalanine with L-tyrosine as the
sole precursor for RA production can save a hydroxylation step. To
do this, we used the tyrosine ammonia lyase from F. johnsoniae (FjTAL) to synthesize pCA from
L-tyrosine.[43] By overexpressing tyrosine
aminotransferase (TAT) from either plant P. scutellarioides (CbTAT) or from rat R. norvegus (RnTAT), and hydroxyphenylpyruvate
reductase from P. scutellarioides (CbHPPR) we were able to synthesize 4-HPL from L-tyrosine as well. The activation
of p-coumaric acid to 4-comaroyl-coA was achieved
by overexpression of 4CL1 of A. thaliana, which was shown to have better performance than the other isoenzymes, 4CL2 and 4CL3.[44] By expressing rosmarinic acid synthase originating from either M. officinalis (MoRAS) or from P. scutellarioides (CbRAS), followed by
overexpression of CYP98A14 hydroxylase and the corresponding
reductase genes from either S. miltiorrhiza (SmCYP98A14-CPR) or from P. scutellarioides (CbCYP98A14-CPR), we successfully assembled the
plant pathway for RA biosynthesis. For high expression of the pathway
enzymes, the enzyme homologues were expressed under the control of
a strong constitutive promoters Ptef1 (transcriptional
elongation factor EF-1α) and Ppgk1 (phosphoglycerate
kinase) as shown in Figure and Figure S3. These promoters
are already characterized to have high constant activity at different
glucose concentrations.[45] For terminator
selection, bidirectional terminators Tadh1 and Tcyc1 were used.[46]
Figure 2
Engineered route for
rosmarinic acid (RA) production in S. cerevisiae.
Native genes are indicated in black, overexpressed
yeast genes in green, overexpressed heterologous genes in purple,
and deleted genes in red. The arrows in orange show the chimeric pathway,
and the arrows in blue are for plant pathway. The aromatic amino acids
are shown in hexagons: E4P, erythrose-4-phosphate; PEP, phosphoenolpyruvate;
DAHP, 3-deoxy-d-arabino-heptulosonate-7-phosphate; EP3P,
5-enolpyruvylshikimate-3-phosphate; CHA, chorismate; L-TRP, L-tryptophan; PPA, prephenate; PPY, phenylpyruvate; L-PHE, L-phenylalanine;
4-HPP, 4-hydroxyphenylpyruvate; L-TYR, L-tyrosine; 4-HPL, 4-hydroxyphenyllactate;
pCA, p-coumaric acid; CA, caffeic acid; 4C-CoA, 4-coumaroyl-coA;
4C-4′HPL, 4-coumaroyl-4′-hydroxyphenyllactic acid; Ca-CoA,
caffeoyl-coA; 3,4-DHPL, 3,4-dihydroxyphenyllactate; RA, rosmarinic
acid.
Figure 3
(A) The full factorial DOE strain construction
with implemented
heterologous plant and chimeric pathways for RA production, along
with the promoters and terminators used to control the expression
of genes. The phenotype of the constructed strains as rosmarinic acid
titer and DCW (g/L) is shown for each construct. The mean value of
response (RA titer) versus levels of each factor is shown in panel
B for plant pathway strains, and panel C for chimeric strains. The
2-way interaction plot for factors affecting fitted means of RA (mg/L)
is also shown for plant strains (D), and for chimeric strains (E).
The values for RA titer and DCW measurements represent the mean of n = 3 biologically independent samples, and error bars show
standard deviation.
Engineered route for
rosmarinic acid (RA) production in S. cerevisiae.
Native genes are indicated in black, overexpressed
yeast genes in green, overexpressed heterologous genes in purple,
and deleted genes in red. The arrows in orange show the chimeric pathway,
and the arrows in blue are for plant pathway. The aromatic amino acids
are shown in hexagons: E4P, erythrose-4-phosphate; PEP, phosphoenolpyruvate;
DAHP, 3-deoxy-d-arabino-heptulosonate-7-phosphate; EP3P,
5-enolpyruvylshikimate-3-phosphate; CHA, chorismate; L-TRP, L-tryptophan; PPA, prephenate; PPY, phenylpyruvate; L-PHE, L-phenylalanine;
4-HPP, 4-hydroxyphenylpyruvate; L-TYR, L-tyrosine; 4-HPL, 4-hydroxyphenyllactate;
pCA, p-coumaric acid; CA, caffeic acid; 4C-CoA, 4-coumaroyl-coA;
4C-4′HPL, 4-coumaroyl-4′-hydroxyphenyllactic acid; Ca-CoA,
caffeoyl-coA; 3,4-DHPL, 3,4-dihydroxyphenyllactate; RA, rosmarinic
acid.(A) The full factorial DOE strain construction
with implemented
heterologous plant and chimeric pathways for RA production, along
with the promoters and terminators used to control the expression
of genes. The phenotype of the constructed strains as rosmarinic acid
titer and DCW (g/L) is shown for each construct. The mean value of
response (RA titer) versus levels of each factor is shown in panel
B for plant pathway strains, and panel C for chimeric strains. The
2-way interaction plot for factors affecting fitted means of RA (mg/L)
is also shown for plant strains (D), and for chimeric strains (E).
The values for RA titer and DCW measurements represent the mean of n = 3 biologically independent samples, and error bars show
standard deviation.As we used two homologues
from different origins for the three
enzymes tyrosine aminotransferase (RnTAT/CbTAT), rosmarinic acid synthase (MoRAS/CbRAS), and CYP98A14 hydroxylase
and reductase (SmCYP98A14-CPR/CbCYP98A14-CPR), we used the full factorial
DOE for strain design and data analysis. The number of enzymes (termed
as Factors of DOE) and the homologues (termed as Levels of DOE) are
3 and 2, respectively, hence a full factorial design would result
in 23 = 8 genotypes (termed as Experiments of DOE) for
plant pathway assembly in yeast. In the same manner, with two homologues
for enzymes tyrosine aminotransferase and rosmarinic acid synthase
for the chimeric pathway, a two-level two-factor DOE of full factorial
would result in 22 = 4 experiments. A schematic overview
of the plant and chimeric pathways is indicated in Figure . As the total number of combinatorial
strain designs is feasible to construct and phenotype experimentally,
we constructed the whole library of strains accordingly and did not
make any fractional factorials to reduce the number of combinatorial
designs.With DOE full factorial strain construction, we ended
up with eight
strains expressing plant pathways and four strains with chimeric pathways,
each design being a unique genetic modification. The gene expression
levels for different Easyclone sites have already been measured by
Jessob-Fabre et al.[47] with fluorescence
protein GFP as the indicator. However, a small variation in GFP-expression
level was also reported.[47] Therefore, to
have a fair comparison, the gene homologues were expressed at similar
loci (Easyclone sites), with similar promoter and terminator sets
(Figure S3), to ensure that the observed
difference in RA titer is not a result of difference in gene expression
level. Next, we screened the constructed strains for the highest rosmarinic
acid production (the desired phenotype), using feed-in-time media
with glucose as the sole carbon source. The DOE full factorial design
with screening results for RA titer and dry cell weight (DCW, g/L)
is shown in Figure . For plant–pathway strains, the model for the prediction
of response was fitted with a quadratic polynomial, with an R-square
of 99.78%. Regression analysis (Supplementary Table S2) showed that of all factors, only the origin of the RAS enzyme had significant influence on rosmarinic acid
titer (F-value = 175, p-value <
0.05). Also the 2-way interaction between the enzymes rosmarinic acid
synthase (RAS) and tyrosine aminotransferase (TAT) with an F-value of 126 had an impact
on the RA titer, while not rejecting null hypothesis (p-value = 0.057). To select for the best combinatorial design of plant
strains, the interaction plot of factors shown in Figure D is used that shows that the
RA mean titer (mg/L) for a plant pathway is the highest when RAS is from M. officinalis, TAT is from P. scutellarioides, and CYP98A14-CPR is from P. scutellarioides. The resulting strain
plant #7 showed the highest RA titer for plant-pathway strains, with
2.95 ± 0.08 mg/L.For chimeric-pathway strains, the linear
model was fitted with
R-square of 79.03%, while the regression analysis (Table S3) of factors did not show any factor as an important
variant in RA titer (p-value > 0.1, F-values close
to 1). The optimal design is again selected based on the interaction
plot of factors shown in Figure E, which shows the highest RA mean titer (mg/L) for
the chimeric pathway is in the design with RAS from P. scutellarioides and TAT from R. norvegus. The resulting strain chimeric #4 produced RA
in a titer of 0.33 ± 0.10 mg/L, which is ca. half of the titer
reported for RA producing E. coli with the same pathway.[17] Heterologous enzymes originating from plants
are reported to be organized in protein complexes, in which the proteins
involved in the pathway can interfere in spatial colocalization of
other proteins. These protein–protein interactions are also
the driving force for coevolution and regulation of the protein structure
of these enzymes.[48] Therefore, the origin
of these proteins plays a significant role in obtained RA titers (Figure A), which also highlights
the fact that these interactions have to be taken into account in
developing cell factories for plant-derived compounds.Apart
from RA titer in the engineered strains, we also measured
the titers of RA biosynthetic intermediates in the extracted samples
(Figure ). A major
difference between the plant and chimeric strains, as seen from this
graph, was the titer of 4-HPP, that is almost a hundred times higher
in plant strains (Figure A) compared to the chimeric ones (Figure B). As the difference between plant and chimeric
strains is in the hydroxylase enzyme that is beyond 4-HPP, then one
should assume that the titers of 4-HPP and 4-HPL must be comparable
between the two types of strains. The observed difference is due to
the promiscuity of enzyme EchpaBC, as this enzyme
is reported to hydroxylate quite a broad range of aromatic compounds,
including L-tyrosine hydroxylation to L-DOPA.[20,49] In principal, the expression of TAL enzyme should
catalyze the conversion of L-DOPA to caffeic acid,[20] which would contribute to the RA synthesis pathway. However,
we could observe a darker color of chimeric strains at the end of
72 h cultivation, compared to the parent strain (Figure S4). Indeed, the produced L-DOPA was partly oxidized
to dark colored-melanin pigment,[50] which
probably drained the L-tyrosine pool and resulted in lower titers
of 4-HPP and 4-HPL in chimeric strains. The parent strain (ST7574)
without precursor supply optimization accumulated 2.91 ± 0.22
mg/L of 4-HPP (Figure B), while the best RA-producing strain plant #7 had 1099 ± 59
mg/L 4-HPP. Similarly, the concentration of the reduced derivative
of 4-HPP, 4-HPL, was 97-fold higher in the precursor-engineered strain
(plant #7) compared to the parent strain. Considering that CoA-ligase
enzyme (At4CL1) is similar in both plant and chimeric
strains, we assumed from titers of pCA and CA in Figure that the amount of 4C-CoA
and Ca-CoA are the limiting substrates for RA production in plant
and chimeric strains, respectively. Based on km values for the enzyme RAS with 4-HPL or
3,4-DHPL as substrate, obtained from The Comprehensive Enzyme Information
System (http://www.brenda-enzymes.org/), there is a higher affinity of RAS enzyme (almost
10 times) to 4-HPL compared to 3,4-DHPL.[19] This seems to be the main reason for the observed difference in
RA synthesis through the plant and chimeric pathways. Moreover, a
comparison of the precursors’ accumulation in plant #7 and
plant #8 in Figure A shows a higher titer of intermediates for plant #7, while the only
difference in the two designs is the RAS homologue,
the second last step of RA biosynthesis that apparently should not
affect precursors accumulation. However, as mentioned earlier, the
protein–protein interactions for MoRAS and CbRAS with the other proteins of the pathway might be different,
influencing the performance of other enzymes that have role in precursors
production. In addition, as concluded from Figure , MoRAS gives higher titers
of RA than CbRAS, so in plant #7, this enzyme can
drive the conversion of intermediates to RA faster and reduce the
accumulation of these compounds.
Figure 4
Precursors titer measured for yeast strains
with (A) plant pathway
and (B) chimeric pathway at the end of production experiment. The
designs of strains plant #1 to plant #8 and chimeric #1 to chimeric
#4 is shown in Figure : 4-HPP, 4-hydroxyphenylpyruvate; 4-HPL, 4-hydroxyphenyllactate;
pCA, p-coumaric acid; 3,4-DHPL, 3,4-dihydroxyphenyllactate;
CA, caffeic acid. The values represent the mean of n = 3 biologically independent samples, and error bars show standard
deviation.
Precursors titer measured for yeast strains
with (A) plant pathway
and (B) chimeric pathway at the end of production experiment. The
designs of strains plant #1 to plant #8 and chimeric #1 to chimeric
#4 is shown in Figure : 4-HPP, 4-hydroxyphenylpyruvate; 4-HPL, 4-hydroxyphenyllactate;
pCA, p-coumaric acid; 3,4-DHPL, 3,4-dihydroxyphenyllactate;
CA, caffeic acid. The values represent the mean of n = 3 biologically independent samples, and error bars show standard
deviation.The high amounts of residual unreacted
metabolites in the RA producing
strains in Figure A suggested a limitation in the activity of HPPR, RAS, and CYP98A14 associated
with CPR enzymes. Hence, we chose three of the high
RA producing strains in Figure , plants #5, #6, and #7, and integrated the second copy of HPPR, RAS, and CYP98A14-CPR. The results of this modification are shown in Figure A, where the highest RA titer
of 5.93 ± 0.06 mg/L was achieved for ST9527, 164% higher than
in the parent strain plant #6 (p = 0.0007). Doubling
the copy number of HPPR, RAS, and CYP98A14 genes also decreased the concentrations of RA intermediates
4-HPP, 4-HPL, and pCA in Figure B (p < 0.01). However, this reduction
in accumulation of intermediates did not result in higher titer of
RA in ST9526 with double-integration of MoRAS, CbHPPR, and CbCYP-CbCPR when compared to its parent strain plant #7 (p =
0.27), and even caused a 91% decrease in RA synthesis of ST9522 compared
to the parent plant #5 (p = 0.0006).
Figure 5
Rosmarinic acid titer
and DCW (A), and the precursor titers (B)
for the strains with integrated second copy of HPPR, RAS, and CYP98A14-CPR genes.
Statistical analysis was performed for RA titer by using Student’s t test (one-tailed, two-sample unequal variances, *p < 0.01, **p < 0.001). The values
represent the mean of n = 3 biologically independent
samples, and error bars show standard deviation.
Rosmarinic acid titer
and DCW (A), and the precursor titers (B)
for the strains with integrated second copy of HPPR, RAS, and CYP98A14-CPR genes.
Statistical analysis was performed for RA titer by using Student’s t test (one-tailed, two-sample unequal variances, *p < 0.01, **p < 0.001). The values
represent the mean of n = 3 biologically independent
samples, and error bars show standard deviation.We speculated if the low RA titer can be related to the toxicity
of the compound to the host organism. We cultivated nonproducing and
RA-producing strains with different concentrations of RA (0.1–5
g/L) and monitored the growth by OD600 measurement (Figure S2). The final OD600 was only
decreased by ca. 25% when RA was added at the highest level of 5 g/L,
hence the compound is not strongly toxic to S. cerevisiae.Despite the fact that the RA titer of 5.93 ± 0.06 mg/L
in
strain ST9527 is the highest titer achieved for production of rosmarinic
acid by a single heterologous microbe using a defined medium, this
titer is still well below the required titer for a competitive production
of RA, and further strain engineering is hence required. The future
strain engineering efforts can comprise the further optimization of
precursor and cofactor supply in the engineering of RA pathway enzymes,
optimizing their expression and localization, and fermentation optimization.
Conclusion
Rosmarinic acid was produced by expressing biosynthetic
enzymes
from plants in yeast S. cerevisiae. The strain was
optimized by selection of optimal enzyme variants, increasing the
gene copy number of the pathway genes, and by improving the precursor
supply through the aromatic amino acids pathway. Up to 5.93 ±
0.06 mg/L rosmarinic acid was produced by engineered yeasts on mineral
medium with glucose as the sole carbon source. This proof-of-concept
study shows the possibility of developing a fermentative process for
rosmarinic acid using a S. cerevisiae cell factory.
Materials
and Methods
Strains and Media
E. coli strain DH5α
was used for cloning and plasmid propagation. Lysogeny Broth (LB)
liquid medium or LB solid medium supplemented with 20 g/L agar containing
100 mg/L ampicillin was used for E. coli cultivation
at 37 °C.The strain CEN.PK 113-7D[42] was used as the parent strain in this study, and the following strain
ST7574 was derived by transforming the episomal vector for expression
of Cas9 protein, with a kanamycin resistance marker (Table S4). To maintain the selection for Cas9, G418 (Sigma-Aldrich)
was supplemented into media at 200 mg/L. Further metabolic engineering
of the yeast cells was carried out by the EasyClone Markerfree toolkit.[47] Briefly, the integrative vectors (Figure S3A–M) were linearized by digestion
with NotI enzyme (New England BioLabs), and together with the corresponding
gRNA helper vector (Figure S3, N) were
transformed into the host yeast strain carrying Cas9 expression plasmid.
Yeast transformation was performed using the standard lithium acetate
method, and the transformants were plated on YPD medium (10 g/L yeast
extract, 20 g/L peptone, 20 g/L glucose) supplemented with antibiotics:
nourseothricin (Jena Bioscience GmbH) at 100 mg/L and G418 (Sigma-Aldrich)
at 200 mg/L. The chemicals were all obtained from Sigma-Aldrich, unless
otherwise mentioned.To verify the correct integration of DNA
fragment into yeast cells,
colony PCR with OneTaq Master Mix (New England BioLabs)
and the set of primers shown and described in Table S8 was used. Each colony PCR reaction contained 1 μL
of each of the primers 1, 2, and 3 (Table S8), 10 μL of OneTaq Master Mix and a small
amount of yeast colony as template, with water to the final volume
of 20 μL. The thermal program used is initial denaturation at
95 °C for 2 min, 30 cycles of denaturation at 95 °C for
20 s, annealing at 55 °C for 20 s, and extension for 72 °C
1 min/kb. The correct tranformants are then cured to lose the gRNA
vector.
Plasmids
All the integrative vectors together with
gRNA vectors are listed in Table S5, and
the plasmid maps of integrative and gRNA vectors are shown in Figure S3. The integrative vectors were assembled
by USER cloning according to Table S5.
Generally, 0.5 μL of CutSmart buffer (NEB) was mixed with 0.5
μL of USER enzyme and 100–200 ng of each BioBrick or
linearized parent vector to a final volume of 5 μL. The parent
vectors contain a USER cloning site surrounded by bidirectional terminators
Tadh1 and Tcyc1. These vectors were
linearized by digestion with FastDigest SfaAI (Life Technologies)
and sticky ends obtained by nicking with Nb.BsmI (New England Biolabs).
The USER reaction was then incubated for 25 min at 37 °C, 15
min at 25 °C, and 10 min at 15 °C, followed by transformation
to E. coli. Correct assembly was verified by DNA
sequencing (Eurofins Genomics, Germany).[47,51]All BioBricks with templates and primers used for USER cloning
are listed in Table S6, with primer sequences
listed in Table S7. For amplification of
BioBricks, Phusion U polymerase chain reaction (PCR) from Thermo Fisher
Scientific was implemented using the following thermal program: Initial
denaturation at 98 °C for 5 min, denaturation at 98 °C for
10 s, 30 cycles of annealing at 52 °C for 10 s, extension at
72 °C for 30 s/kb.[51]
Enzyme Genes
The heterologous pathway for rosmarinic
acid production from l-tyrosine was constructed in yeast
by implementing the genes 4-coumaryl coA-ligase from Arabidopsis
thaliana (At4CL1), tyrosine ammonia lyase
from Flavobacterium johnsoniae (FjTAL), tyrosine aminotransferase from P. scutellarioides (CbTAT) and from Rattus norvegus (RnTAT), hydroxyphenylpyruvate reductase from P. scutellarioides (CbHPPR), rosmarinic
acid synthase from P. scutellarioides (CbRAS) and from M. officinalis (MoRAS), 4-hydroxyphenylacetate 3-monooxygenase complex B and C from E. coli (EchpaB, EchpaC), cytochrome P450-dependent hydroxylase from S. miltiorrhiza (SmCYP98A14) and from P. scutellarioides (CbCYP98A14), and the corresponding cytochrome
P450 reductases (SmCPR and CbCPR). It should be noted that throughout this study, for the nomenclature
of the genes originated from P. scutellarioides,
the former name of this plant Coleus blumei (Cb) is used. Synthetic genes were ordered in codon-optimized
variants for S. cerevisiae from GeneArt (Thermo Fisher
Scientific). The codon-optimized nucleotide sequences for all the
synthetic genes are listed in Table S9.
Statistical Analysis
The regression and statistical
analysis of variances (ANOVA) of the model was performed using Minitab19.2
software. To construct the strains, a two-level full factorial design
was used in order to evaluate the effect of the combination of gene
homologues in such a way to maximize RA titer as the response. Full
factorial design allows for studying all possible combinations of
the levels in the factors in the strain construction and also evaluate
the joint effect of the factors on the response.[52] The factors and levels are described in Table . As such, 23 = 8
strains for plant pathway, and 22 = 4 strains for chimeric
pathway were constructed according to this experimental design.
Table 1
Factors and Levels Used for Full-Factorial
DOE of Strain Construction
levels
factors
1
2
rosmarinate synthase (RAS) homologues
M. officinalis (MoRAS)
P. scutellarioides (CbRAS)
tyrosine aminotransferase (TAT) homologues
R. norvegus (RnTAT)
P. scutellarioides (CbTAT)
cytochrome P450-dependent hydroxylase (CYP) and reductases (CPR) homologues
S. miltiorrhiza (SmCYP98A14-CPR)
P. scutellarioides (CbCYP98A14-CPR)
As part of the ANOVA analysis,
the F-test was
used to determine the statistical significance of the effect of each
factor (the genes RAS, TAT, and CYP98A14-CPR) on the final response (rosmarinic acid titer).
The F-value (and also p-value) of
each factor in the DOE design is shown in Tables S2 and S3. It should be noted that a larger F-value for a factor means that the variation of the two mean production
titers at 2 levels (gene origins) is significant, and the change in
this factor has a large effect on the RA titer.[31] The F-value is calculated as described
by Zhou et al.[31] The p-value is also calculated using Minitab19.2 software, with a significance
of α = 0.05.
Rosmarinic Acid Production
The screening
of constructed
yeast strains for RA production was carried out in 24-deep-well plates
with air-penetrable metal lids (EnzyScreen, The Netherlands) containing
2 mL of fresh mineral medium, which contains 7.5 g/L (NH4)2SO4, 14.4 g/L KH2PO4, 0.5 g/L MgSO4·7H2O, 2 mL/L trace metal
(3.0 g/L FeSO4·7H2O, 4.5 g/L ZnSO4·7H2O, 4.5 g/L CaCl2·2H2O, 0.84 g/L MnCl2·2H2O, 0.3 g/L CoCl2·6H2O, 0.3 g/L CuSO4·5H2O, 0.4 g/L Na2MoO4·2H2O, 1.0 g/L H3BO3, 0.1 g/L KI, and 19.0 g/L
Na2EDTA·2H2O), and 1 mL/L vitamin solutions
(0.05 g/L D-biotin, 1.0 g/L D-pantothenic acid hemicalcium salt, 1.0
g/L thiamin–HCl, 1.0 g/L pyridoxin–HCl, 1.0 g/L nicotinic
acid, 0.2 g/L p-aminobenzoic acid, and 25.0 g/L myo-inositol).[53] To mimic fed-batch
fermentation, 60 g/L polysaccharide powder (EnPump Substrate, Enpresso
GmbH, Germany) with an enzyme mix of final concentration of 0.3% v/v
(Reagent A, Enspresso GmbH, Germany) was added to the mineral media
immediately before use. To prevent RA degradation, 10 mM filter-sterile
ascorbic acid was supplemented to the media right before inoculation.
Metabolite Extraction
The preculture of each yeast
strain was grown in 5 mL of YPD medium in 13 mL tubes overnight at
30 °C and 250 rpm. The inoculation of all strains was done with
an adequate amount of preculture to obtain the starting OD600 = 0.1. The plates were light-protected, and incubated at 30 °C
with shaking at 300 rpm at 5 cm orbit cast. Samples were taken after
72 h and analyzed for cell growth and metabolite extraction. The optimized
extraction method was as follows: 800 μL of the culture was
mixed 1:1 (v:v) with absolute ethanol supplemented with 0.01% w/v
3,5-di-tert-4-butylhydroxyltoluene (BHT). The mixture
was then shaken vigorously using the Precellys T 24 homogenizer (Bertin
Corp.) in three cycles of 6500 rpm for 45 s to disrupt the cells.
After the disruption, the cell debris was separated by centrifuging
for 30 min at 21 000g, and the supernatant
was moved to amber-colored HPLC vials for metabolite analysis.
Analytical
Methods
Cell growth was monitored by measuring
the optical density at 600 nm (OD600) using a NanoPhotometer
(Implen GmbH, Germany). The values were then used to calculate dry
cell weight (DCW) of the culture in g/L using the following empirical
equation:For metabolite
quantification, the standards
for rosmarinic acid (RA), 3,4-dihydroxyphenyllactic acid (3,4-DHPL),
p-coumaric acid (pCA), caffeic acid (CA), 4-hydroxyphenyllactic acid
(4-HPL), and 4-hydroxyphenylpyruvic acid (4-HPP) with certified purities
greater than 96% were purchased from Sigma-Aldrich (St. Louis, Missouri,
USA). The LC system consisted of an Advance liquid chromatograph (Bruker,
Fremont, CA, USA) equipped with a solvent delivery compartment with
high-pressure mixing, a column compartment, and a CTC auto sampler.
The injection volume was 1 μL. The separation of compounds was
performed on an ACQUITY UPLC HSS T3, 100 mm × 2.1 mm, 1.8 μm
particle size (Waters, Ireland). In front of the separation column
was a Phenomenex krudkatcher filter, 0.5 μm. The total flow
rate of eluent A (Milli-Q water with 0.1% formic acid) and B (acetonitrile
with 0.1% formic acid) was 0.5 mL min–1. The initial
gradient was 100% and held for 1 min, decreasing to 5% after 4 min
and held for 1 min, then back to 100% after 0.1 min and held at 100%
for 0.9 min. The total run time was 6 min. The column temperature
was set at 45 °C. The MS/MS detection was performed on an EVOQ
triple quadrupole instrument (Bruker, Fremont, CA, USA) equipped with
an atmospheric pressure ionization (API) interface. The mass spectrometer
was operated with electrospray both in the negative-ion mode (ESI–). The capillary voltage was set to 3000 V. The heated
probe temperature was 350 °C, and the heated probe gas flow was
40 L h–1. The cone gas flow and temperature were
20 L/h and 350 °C, respectively. Nebulizer gas flow was set at
40 L/h, and the exhaust gas was turned on. Argon was used as the collision
gas at a pressure of 1.5 mTorr. Detection was performed in multiple
reacting monitoring (MRM) mode. The collision energies were optimized
for the different compounds.
Authors: Ying Zhang; Jonathan P Smuts; Edra Dodbiba; Rekha Rangarajan; John C Lang; Daniel W Armstrong Journal: J Agric Food Chem Date: 2012-08-28 Impact factor: 5.279
Authors: Inês Mansinhos; Sandra Gonçalves; Raquel Rodríguez-Solana; Hugo Duarte; José Luis Ordóñez-Díaz; José Manuel Moreno-Rojas; Anabela Romano Journal: Antioxidants (Basel) Date: 2022-07-28